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Department of Internal Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania
BACKGROUND
•  Thrombotic Thrombocytopenic Purpura (TTP) is 
a rare and life-threatening coagulation disorder 
caused by antibodies against ADAMTS13.  
Loss of ADAMTS13 activity can lead to organ 
ischemia and thrombi formation secondary to 
depletion of hemostatic factors. It is reported 
that approximately 15-41% of TTP cases are 
complicated with a myocardial infarction (MI). 
CASE PRESENTATION
•  A 57-year-old female presented to the ER with 
complaints of hematuria and abdominal pain.
•  Labs demonstrated Hgb 8.0 g/dL, Platelets 9.0 
thou/cmm, LDH 9342 u/L, Direct bilirubin 2.0 
mg/dL (Total bilirubin 6.6 mg/dL), INR 1.9,  
SCr 2.46 mg/dL (baseline <1.0 mg/dL), and 
Troponin 8.41 ng/L.
•  Peripheral smear demonstrated schistocytes.
•  The patient was clinically diagnosed with TTP. 
INTERVENTIONS
•  The patient was administered FFP and  
started on plasmapheresis to reduce antibody 
mediated destruction of ADAMTS13. 
RESULTS
•  ADAMTS13 activity was obtained which 
resulted at 2.0% (normal >66%).
•  Unfortunately, the patient went into PEA arrest 
with EKG revealing STEMI in leads 2,3, avF 
and V1-V2. Catheterization (PCI) was deemed 
too high risk for bleeding and renal failure 
considering the patient’s AKI and 
thrombocytopenia. Resuscitative measures 
were stopped after 5 rounds of CPR.
DISCUSSION
•  MI is a well described complication of TTP; 
however, subsequent management remains 
controversial.
•  Recently, studies have shown a potential role 
for corticosteroids and Rituxan in order reduce 
thrombi formation; neither of which were used 
in our patient. 
•  This presentation illustrates the importance of 
acknowledging MI as a common complication 
of TTP and brings to attention the role of 
immunosuppressive agents as possible 
therapies in cases where PCI is 
contraindicated.
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